Disease specific guidelines for ling transplantation full details for md exam answer 15 marks
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive, detailed data for the disease-specific guidelines. Let me compile the full MD exam answer.
Disease-Specific Guidelines for Lung Transplantation
[15-Mark MD Exam Answer]
Introduction
Lung transplantation remains the definitive treatment for select patients with end-stage lung disease not amenable to other therapies. Since 1998, the International Society for Heart and Lung Transplantation (ISHLT) has produced and updated consensus guidelines for candidate selection (most recently updated in 2021). The Lung Allocation Score (LAS) system introduced in 2007 has significantly altered the disease distribution — restrictive lung diseases (primarily IPF) now constitute ~60% of all US lung transplants, surpassing COPD.
ISHLT General Criteria for Lung Transplantation
Before disease-specific criteria, all candidates must meet the following three general ISHLT criteria (Table 39.3):
| Criterion | Threshold |
|---|---|
| Risk of death from lung disease without transplant | >50% within 2 years |
| Likelihood of surviving ≥90 days post-transplant | >80% |
| Likelihood of 5-year post-transplant survival (with adequate graft function) | >80% |
Disease Classification Groups (UNOS/OPTN)
Lung transplant diseases are categorized into four groups:
- Group A – Obstructive (COPD, emphysema, alpha-1 antitrypsin deficiency, LAM, bronchiectasis)
- Group B – Pulmonary Vascular (PAH, pulmonary veno-occlusive disease, portopulmonary HTN)
- Group C – Cystic Fibrosis and Immunodeficiency
- Group D – Restrictive (IPF, ILD, sarcoidosis with mPAP >30 mmHg, ARDS)
Disease-Specific Listing Guidelines (ISHLT 2021 / Table 39.4)
1. Interstitial Lung Disease (ILD) / Idiopathic Pulmonary Fibrosis (IPF)
Referral: Early referral following radiologic or histologic diagnosis, regardless of lung function.
IPF is now the #1 indication for lung transplantation in the US (since 2007 with LAS implementation). Median survival after IPF diagnosis is <5 years.
Listing criteria (any one of the following):
| Criterion | Threshold |
|---|---|
| Decline in FVC | ≥10% over 6 months (a 5% decline may also warrant listing) |
| Decline in DLCO | ≥15% over 6 months |
| Desaturation on 6MWT | SpO₂ <88%, or 6MWT distance <250 m, or decline of ≥450 m over 6 months |
| Pulmonary hypertension | On right heart catheterization or echocardiography |
| Hospitalization | Due to respiratory decline, pneumothorax, or acute exacerbation |
Post-transplant outcomes for IPF are the worst of all disease groups at 10 years, yet transplantation provides survival benefit vs medical therapy alone.
2. Chronic Obstructive Pulmonary Disease (COPD) / Emphysema
COPD is the 2nd most common indication, constituting ~24% of US lung transplants (obstructive group). Patients with COPD have the best 1-year survival (shared with CF) but lower 10-year survival compared to most except IPF.
Referral criteria:
- BODE Index ≥5 (Body mass index, airflow Obstruction, Dyspnea, Exercise capacity)
Listing criteria (any one of the following):
| Criterion | Threshold |
|---|---|
| BODE Index | ≥7–10 |
| FEV₁ | <20% predicted |
| BODE Index 5–6 with rapid decline, frequent exacerbations, or pulmonary hypertension | |
| Hospitalizations for acute exacerbation with hypercapnia | PaCO₂ >50 mmHg |
| Pulmonary hypertension or cor pulmonale despite O₂ therapy | |
| Homogeneous distribution of emphysema or upper lobe emphysema | (not candidate for LVRS) |
Note: Lung volume reduction surgery (LVRS) should be considered before transplant in upper-lobe predominant emphysema with poor exercise capacity.
3. Cystic Fibrosis (CF) and Bronchiectasis
CF is the 3rd most common indication, representing ~13% of adult transplants worldwide and ~10% in the US. CF recipients show the highest long-term survival — even up to 20 years — and share best 1-year survival with COPD. Bilateral sequential lung transplant is mandatory in CF due to the infected native lung reservoir.
Listing criteria (any one of the following):
| Criterion | Threshold |
|---|---|
| FEV₁ | <30% predicted or rapid decline |
| 6MWT distance | <400 m |
| Pulmonary hypertension | |
| Worsening nutritional status (BMI <18 kg/m²) | |
| Increasing frequency of hospitalizations | |
| Massive hemoptysis or recurrent pneumothorax | |
| Hypoxemia (SpO₂ <88%) at rest or with exertion | |
| Hypercapnia (PaCO₂ ≥50 mmHg) | |
| Female sex (independently associated with worse outcomes) | Listed at higher FEV₁ values |
Special consideration — Organism resistance:
- Pan-resistant Pseudomonas aeruginosa: Poorer outcomes but comparable to general UNOS registrants — not an absolute contraindication at most centers
- Burkholderia gladioli and certain Burkholderia cenocepacia strains: Associated with excess mortality in the first 6 months post-transplant — considered relative-to-absolute contraindications at most programs
4. Pulmonary Arterial Hypertension (PAH)
PAH is the prototype of Group B. Bilateral lung transplant is preferred (vs. heart-lung transplant) as RV function typically recovers with pressure relief.
Listing criteria (any one of the following):
| Criterion | Threshold |
|---|---|
| NYHA/WHO Functional Class III–IV despite maximal therapy | |
| Rapidly progressive disease | |
| Use of parenteral prostanoid therapy | |
| 6MWT distance | <350 m or declining |
| Cardiac Index | <2.0 L/min/m² |
| Right atrial pressure | >15 mmHg |
| Hemoptysis, pericardial effusion, or signs of progressive RV failure |
Pre-induction ECMO should be considered in patients with near-suprasystemic PA pressures to prevent hemodynamic collapse.
5. Sarcoidosis
Sarcoidosis listed under restrictive (Group D) when mPAP >30 mmHg, or obstructive (Group A) when mPAP ≤30 mmHg.
Listing criteria:
- NYHA Class III–IV dyspnea
- Hypoxemia at rest or with exertion
- Pulmonary hypertension
- Declining 6MWT
Sarcoidosis can recur in the allograft, but this rarely results in graft failure.
6. Lymphangioleiomyomatosis (LAM)
- FEV₁ <30% predicted or rapid decline in lung function
- Severely impaired exercise capacity (VO₂ max <50% predicted)
- Hypoxemia at rest
Sirolimus (mTOR inhibitor) stabilizes disease; transplant is reserved for end-stage LAM.
7. Alpha-1 Antitrypsin Deficiency (AATD)
Disease falls in Group A (obstructive). Criteria are similar to COPD:
- BODE index ≥7–10
- Rapid functional decline despite augmentation therapy
- FEV₁ <20% predicted
General Contraindications to Lung Transplantation
Absolute Contraindications:
- Active or recent (within 2 years) malignancy (except some skin cancers)
- Uncontrolled extrapulmonary infection (including HIV with detectable viral load, active TB, hepatitis B/C with cirrhosis)
- Significant dysfunction of other vital organs (GFR <20 mL/min unrelated to pulmonary disease — consider heart-lung-kidney)
- Non-correctable coagulopathy
- Active substance use (tobacco, alcohol, illicit drugs — minimum 6 months cessation required)
- Non-adherence to medical therapy
- Morbid obesity (BMI ≥35 kg/m²) — absolute contraindication at most centers
Relative Contraindications:
- Age >65 years (though not absolute; many centers transplant up to age 70 with careful selection)
- Severe malnutrition (BMI <17 kg/m²)
- Severe osteoporosis
- Mechanical ventilation or ECMO dependence (increased risk but not absolute)
- Extensively drug-resistant organisms (e.g., Mycobacterium abscessus in CF)
- Moderate renal dysfunction (GFR 20–50 mL/min)
- Psychosocial barriers or inadequate social support
Type of Transplant by Disease
| Disease | Preferred Transplant Type |
|---|---|
| IPF | Single or bilateral (bilateral gives better survival) |
| COPD/Emphysema | Bilateral preferred (single acceptable) |
| Cystic Fibrosis | Bilateral mandatory |
| PAH | Bilateral (heart-lung if irreversible RV failure) |
| Sarcoidosis | Bilateral |
| LAM | Single or bilateral |
| Bronchiectasis | Bilateral mandatory |
Post-Transplant Outcomes by Disease
| Disease Group | Median Survival |
|---|---|
| CF | Best — highest at 20 years |
| COPD | Good 1-year survival; lower 10-year |
| PAH | Good 1-year survival |
| IPF | Worst — poorest long-term survival |
| Sarcoidosis | Intermediate |
Key Complications Post-Transplant
-
Primary Graft Dysfunction (PGD): Acute lung injury within 72 hours; defined by PaO₂/FiO₂ <300 with radiographic infiltrates. Graded 0–3. Associated with 3–5× increased mortality. Risk factors: donor smoking history, FiO₂ >0.4 at reperfusion, sarcoidosis or PAH in recipient, CPB use, obesity.
-
Chronic Lung Allograft Dysfunction (CLAD): Leading cause of late mortality; encompasses Bronchiolitis Obliterans Syndrome (BOS) and Restrictive Allograft Syndrome (RAS).
-
Infections: Bacterial (esp. Pseudomonas), CMV, fungal (Aspergillus), PCP — prophylaxis mandatory.
-
Post-Transplant Lymphoproliferative Disorder (PTLD): 5% incidence at 1 year, rising to 20% at 5 years; EBV-associated B-cell lymphoma most common.
-
Airway complications: Anastomotic dehiscence/stenosis (2–18% in contemporary series).
Summary for Exam
Remember the BODE Score 7-10 for COPD; FVC ≥10% decline or FEV₁ <30% for ILD/CF; NYHA Class III–IV for PAH. CF needs BILATERAL transplant mandatory. IPF is now the #1 indication post-LAS. Burkholderia cenocepacia is a near-absolute contraindication in CF. CLAD/BOS is the primary cause of long-term graft failure.
Sources: Mulholland and Greenfield's Surgery (7e), Fishman's Pulmonary Diseases and Disorders (2-Vol Set), Murray & Nadel's Textbook of Respiratory Medicine — ISHLT 2015/2021 consensus guidelines
This is a shared conversation. Sign in to Orris to start your own chat.